Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.6% and the Health Care Select Sector SPDR Fund (XLV) adding 0.8%.
The iShares Biotechnology ETF (IBB) climbed 1.7%.
In corporate news, BridgeBio Pharma (BBIO) shares surged 18%. The firm said late Friday the US Food and Drug Administration approved Attruby for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Intellia Therapeutics (NTLA) shares popped 4% after the company said Monday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to nexiguran ziclumeran for the treatment of hereditary transthyretin amyloidosis with polyneuropathy.
Cassava Sciences (SAVA) shares plunged past 82% after the company said its late-stage trial of simufilam in mild-to-moderate Alzheimer's disease didn't meet the co-primary endpoints of cognitive and functional improvement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。